Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer

NTRK gene fusions affecting the tropomyosin receptor kinase (TRK) protein family have been found to be oncogenic drivers in a broad range of cancers. Small molecule inhibitors targeting TRK activity, such as the recently Food and Drug Administration-approved agent larotrectinib (Vitrakvi®), have sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Derek, Yip, Stephen, Sorensen, Poul H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297824/
https://www.ncbi.nlm.nih.gov/pubmed/31256325
http://dx.doi.org/10.1007/s12253-019-00685-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297824/
https://www.ncbi.nlm.nih.gov/pubmed/31256325
http://dx.doi.org/10.1007/s12253-019-00685-2

Ejemplares similares